Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials


The Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the cardiovascular partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
October 2022
Number of pages
Product type
Therapy profile
Available formats
PDF document
Report edition

Global Cardiovascular Partnering 2015 to 2022 provides the full collection of Cardiovascular disease deals signed between the world’s pharmaceutical and biotechnology companies since 2015.


  • Trends in Cardiovascular partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Cardiovascular partnering agreement structure
  • Cardiovascular partnering contract documents
  • Top Cardiovascular deals by value
  • Most active Cardiovascular dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.


The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Cardiovascular dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Cardiovascular dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Cardiovascular deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Cardiovascular dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 5 provides comprehensive access to Cardiovascular deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Cardiovascular partnering deals by specific Cardiovascular target announced since 2015. The chapter is organized by specific Cardiovascular therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Cardiovascular partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Cardiovascular partnering and dealmaking since 2015.      


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cardiovascular technologies and products.


Report scope


Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to cardiovascular trends and structure of deals entered into by leading companies worldwide.


Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials includes:


  • Trends in cardiovascular dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of cardiovascular deal contract documents
  • Access to cardiovascular deal records
  • The leading cardiovascular deals by value since 2015
  • Most active cardiovascular dealmakers since 2015


The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.


In Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Cardiovascular Partnering 2015-2022: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for cardiovascular deals. Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Cardiovascular Partnering 2015 to 2022 provides the reader with the following key benefits:


  • In-depth understanding of Cardiovascular deal trends since 2015
  • Access Cardiovascular deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Cardiovascular partner companies
  • Comprehensive access to links to actual Cardiovascular deals entered into by the world’s biopharma companies
  • Indepth review of Cardiovascular deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Cardiovascular opportunities
  • Uncover companies actively partnering Cardiovascular opportunities

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Cardiovascular dealmaking


2.1. Introduction

2.2. Cardiovascular partnering over the years     

2.3. Cardiovascular partnering by deal type

2.4. Cardiovascular partnering by industry sector

2.5. Cardiovascular partnering by stage of development

2.6. Cardiovascular partnering by technology type

2.7. Cardiovascular partnering by therapeutic indication


Chapter 3 – Financial deal terms for Cardiovascular partnering


3.1. Introduction

3.2. Disclosed financials terms for Cardiovascular partnering

3.3. Cardiovascular partnering headline values

3.4. Cardiovascular deal upfront payments

3.5. Cardiovascular deal milestone payments

3.6. Cardiovascular royalty rates


Chapter 4 – Leading Cardiovascular deals and dealmakers


4.1. Introduction

4.2. Most active in Cardiovascular partnering

4.3. List of most active dealmakers in Cardiovascular    

4.4. Top Cardiovascular deals by value


Chapter 5 – Cardiovascular contract document directory


5.1. Introduction

5.2. Cardiovascular partnering deals where contract document available


Chapter 6 – Cardiovascular dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by Cardiovascular therapeutic target




Appendix 1 – Directory of Cardiovascular deals by company A-Z since 2015

Appendix 2 – Directory of Cardiovascular deals by deal type since 2015

Appendix 3 – Directory of Cardiovascular deals by stage of development since 2015

Appendix 4 – Directory of Cardiovascular deals by technology type since 2015

Further reading on dealmaking

Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from CurrentPartnering


Table of figures


Figure 1: Cardiovascular partnering since 2015

Figure 2: Cardiovascular partnering by deal type since 2015

Figure 3: Cardiovascular partnering by industry sector since 2015

Figure 4: Cardiovascular partnering by stage of development since 2015

Figure 5: Cardiovascular partnering by technology type since 2015

Figure 6: Cardiovascular partnering by indication since 2015

Figure 7: Cardiovascular deals with a headline value

Figure 8: Cardiovascular deals with upfront payment values

Figure 9: Cardiovascular deals with milestone payment

Figure 10: Cardiovascular deals with royalty rates

Figure 11: Active Cardiovascular dealmaking activity since 2015

Figure 12: Top Cardiovascular deals by value since 2015

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1A Pharma, 3M, 3PrimeDx, 4D Molecular Therapeutics, 4D Pharma, 510 Kardiac Devices, A&E Medical, A*STAR Agency for Science, Technology and Research, Abacus Diagnostica, Abbisko Therapeutics, Abbott Laboratories, Abbott Vascular Devices, Abiomed, Ab Medica, Abram Scientific, Acarix, Acasti Pharma, Acceleron Pharma, Accenture, Access Scientific, Access Vascular, AccurKardia, Accuron Technologies, ACEA Biosciences, Acino Pharma, ACIST Medical Systems, Actelion, Actuated Cardio Engineering, Actuated Medical, Acutus Medical, ADAS 3D Medical, AddUp, Adhera Therapeutics, Admedus, Admera Health, Advanced BioInformatics, Advanced BioScience Laboratories, Advanced Catheter Therapies, Advanced Cooling Therapy, Advanz Pharma, Adventus Ventures, Aegerion Pharmaceutical, Aerolase, Affera, AFFiRiS, Agena Bioscience, AgeX Therapeutics, Agilent Technologies, Akcea Therapeutics, Akebia Therapeutics, Akers Biosciences, Akrimax Pharmaceutical, Akums Drugs and Pharmaceuticals, Alere, Aleris, Alexion Pharmaceuticals, Al Hafez Trading Establishment, Alibaba Health, AliveCor, ALK-Abello, Allegis Pharmaceuticals, Allelica, Allergan, Alliance Medical, Allscripts, Alnylam Pharmaceuticals, Altrix Medical, Alyvant, Amarin, Amarna Therapeutics, American College of Cardiology, American College of Surgeons, American Heart Association, American Medical Depot, Amgen, Amneal Pharmaceuticals, Amomed Pharma, Amryt, AnaBios, Analog Devices, AnaMar, Angel Medical Systems, AnGes MG, Angiodynamics, Angiogenesis Foundation, Angion Biomedica, Angionetics, AngioSoma, Angiotech Pharmaceuticals, ANI Pharmaceuticals, Antares Pharma, Antaros Medical, Anthos Therapeutics, APAC Scientific, Apicore, Aplagon, Apotex, Apple, Aptahem, Aptus Endosystems, Aralez Pharmaceuticals, Arbor Pharmaceuticals, Ardelyx, Arena Pharmaceuticals, argenx, Argon Medical Devices, Armetheon, Aronora, Arrowhead Pharmaceuticals, Arsenal Medical, Arteriae, Arterial Health International, Arteriomed, Artio Medical, Artrya, Asahi Intecc, Asahi Kasei, Ascendent Capital Partners, Ascyrus Medical, Asklepios Biopharmaceutical, Aspen Holding, Aspen Pharmacare Canada, Aspire Health Science, Astellas Pharma, AstraZeneca, AstraZeneca HealthCare Foundation, AtCor Medical, Atelerix, Athena Bioscience, Athersys, Atlas Genomics, Atnahs Pharma, Atricure, Audentes Therapeutics, Aurora Resurgence, Aurum Healthcare, Autotelic, Autotelic BIO, Avania, Avery Therapeutics, Avicenna Technology, Aviir Diagnostics, Avrobio, Axiogenesis, Axol Bioscience, Aziyo Biologics, Azurity Pharmaceuticals, B-Secur, Baker IDI Heart and Diabetes Institute, BALT, Bank of China Group Investment, Bardy Diagnostics, Baxter International, Bayer, Bayer Healthcare, Bay Labs, Baylis Medical, Baylor College, B Braun, Beckman Coulter, Becton Dickinson, Beijing Leadman Biochemistry, Beijing SL Pharma, Bened Biomedical, BenevolentAI, Berg, Bertin Pharma, Beth Israel Deaconess Medical Center, Better Therapeutics, Bicycle Therapeutics, Bina Technologies, BioCardia, Biocerna, Biocon, Biofourmis, BioIntelliSense, BioInvent, BioLamina, BIOLIFE4D, BioMarin Pharmaceutical, BioMatrix Specialty Pharmacy, Biomerics, BioPep, Biosense Webster, BioSig Technologies, Biostar Pharmaceuticals, Biotectix, BioTelemetry, Biotricity, Biotronik, BioVectra, Bioventix, BioVentrix, Biovic Sdn bhd, Bird Foundation, BiVACOR, Blackstone Medical, Blockade Medical, BlueRock Therapeutics, BodyTrace, Boehringer Ingelheim, Boston Medical Center, Boston Pharmaceuticals, Boston Scientific, Bracco Diagnostics, BridgeBio Pharma, Brigham and Women's Hospital, Brigham Young University, BrightInsight, Bristol-Myers Squibb, Broad Institute, Brooks Automation, BSN Medical, Burgerhospital, Burke Therapeutics, Butterfly Network, C2Dx, Cadila Pharmaceuticals, Caisson Interventional, Caladrius Biosciences, California Institute for Regenerative Medicine, California Institute of Technology, Canadian Institutes of Health Research, Canon BioMedical, Cantargia, Cap Alter Pharma, Capellabio, Capricor Therapeutics, Capsule Tech, Cardea Associates, Cardiac Insight, Cardiac Science, Cardialen, CardiAQ Valve Technologies, CardieX, Cardinal Health, CardiNor, CardioDx, CardioFocus, Cardiogen Sciences, CardioLabs, Cardiolink, Cardiologs, Cardiome Pharma, CardioNavix, Cardio Partner Resources, Cardiovalve, Cardiovascular Research Foundation, Cardiovascular Solutions of Central Mississippi, Cardiovascular Systems, Cardiowise, Cardioxyl Pharmaceuticals, Cardiva Medical, Cardurion Pharmaceuticals, CareLearning, CarePICS, Carestream Health, CareTaker Medical, Carmat, Carmel Pharma, Carrum Health, Casebia Therapeutics, Case Western Reserve University, CASI Pharmaceuticals, CAS Medical Systems, Catheter Precision, CBL Patras, CB Scientific, CDC Foundation, CDH Capital, Ceapro, Cedars-Sinai Health System, Cedars-Sinai Medical Center, Celladon, Cell and Gene Therapy Catapult, CELLINK, CellProThera, Cell Therapy, Celltrion, Cellular Logistics, CeloNova BioSciences, Celyad, Center for Advancing Point of Care Technologies, Center for Biomarker Research in Medicine, Centerline Biomedical, Cevec Pharmaceuticals, Chameleon BioSurfaces, Chansu Vascular Technologies, Charles River Laboratories, Cheil Pharm, Cheplapharm Arzneimittel, Chiesi Farmaceutici, Children's Heart Foundation, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Medical Research Institute, Children's Minnesota, Children’s Hospital Oakland Research Institute (CHORI), China Grand Pharmaceutical, China Medical System, Chinese Future Industry Investment Fund, Chinese Society of Cardiology, Chong Kun Dang, C Illies, CinCor Pharma, Cipherome, Cipher Pharmaceuticals, Cipla, Circle cardiovascular imaging, Citius Pharmaceuticals, Civica Rx, Clarity Pharmaceuticals, ClearFlow, Cleerly, Cleveland Clinic, Cleveland HeartLab, Clinlogix, Coala Life, Coeptis Pharmaceuticals, Cofactor Genomics, Coherex Medical, Colibri Heart Valve, College of Life Science of Northwest University, Columbia University Medical Center, Conavi Medical, Concordia Healthcare, Contatti Medical, Contour Therapeutics, Cook Medical, Cordis, CorDynamics, CoreRx Pharma, Coretherapix, Corindus Vascular Robotics, CorMatrix Cardiovascular, Coroneo, CorpMedical, Correvio Pharma, CorVascular, Corvia Medical, Corvida Medical, Corvidia Therapeutics, Cosette Pharmaceuticals, Covalon Technologies, Covance, Covis Pharmaceutical, Cranford Pharmaceuticals, C R Bard, Creagh Medical, CRISPR Therapeutics, Critical Diagnostics, Crown Bioscience, Cryolife, Cryothermic Systems, CSL, Curadev Pharma, Cure Duchenne, CVie, CyberHeart, Cyberonics, Cyclenium Pharma, Cyclerion Therapeutics, Cyclofluidic, Cynata Therapeutics, Cytokinetics, CytoSorbents, Daewoong Pharmaceutical, Daiichi Sankyo, DalCor Pharmaceuticals, Dalhousie University, Dassault Systems, Datos Health, DaVinci Biomedical Research Products, Daxor, deCODE Genetics, Delta, Deltex Medical, Denovium, Denovo Biopharma, Department of Defense, Desma HC, Devoro Medical, Dewpoint Therapeutics, Dexcel Pharma, DHR Health, Diablo Clinical Research, diaDexus, DiA Imaging Analysis, Diaxonhit, Dicerna Pharmaceuticals, DiNAQOR, Dizal Pharmaceutical, DKSH, Dogma Therapeutics, Domainex, Dorizoe Lifesciences, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, Duke University Medical Center, DXE Medical, Dyno Therapeutics, Eagle Pharmaceuticals, EB Neuro, Ebn Sina Medical, EchoNous, Eddingpharm, Edwards Lifesciences, EHT Technologies, Eidos Therapeutics, Eiger BioPharmaceuticals, Eko, ELC Group, Electrical Geodesics, Elexopharm, Eli Lilly, Elucid Bioimaging, Embolitech, EmboMedics, Emory University, Enamine, Endo International, Endologix, Endospan, Endotronix, ENYO Pharma, Epsilon, Er-Kim, Erasmus University Medical Center, ERS Genomics, Esaote, Esperion Therapeutics, Espero Biopharma, Etiometry, Eureka Eurostars, European Innovation Council, European Wellness Biomedical Group, Event Cardio Group, Everest Medicines, Eversana, Excelera Network, Exelixis, ExScientia, FABPulous, Farapulse, FarmaMondo Group, FarrowMed, Feinstein Institute for Medical Research, FEops, FibriCheck, Filterlex Medical, Fine Foods & Pharmaceuticals N.T.M., First Check Diagnostics, FitBit, Flow Forward Medical, Food and Drug Administration (FDA), Fortress Biotech, Frankfurt University Hospital, Fresenius Medical Care, Frontier Biotech, FSD Pharma, Fujifilm, Fujifilm medical systems, Fuji Yakuhin, Fulcrum Therapeutics, Fundacion Progreso y Salud, Fu Wai Hospital, G3 Pharmaceuticals, G3 Therapeutics, Galenicum Health, Gardia Medical, Gatehouse Bio, GC Pharma, GE Healthcare, Geisinger Medical Center, Gemphire, Genesis MedTech, Genetrix, GENinCode, Genome Biologics, Genomic Vision, Genpharm, George Clinical, Georgia Institute of Technology, German Ministry for Education and Research, Gestion Univalor, Getinge, GL Capital Group, Global Genomics Group, GNS Healthcare, Goro Healthcare, Grunenthal, GS, Guangdong Provincial People's Hospital, Guerbet, Gyrus Capital, H2-Pharma, Hadasit Medical Research Services and Development, Haemonetics, Hainan Sihuan Pharmaceutical, Hancock Jaffe Laboratories, Hanmi Pharmaceutical, Hansen Medical, Harvard Apparatus Regenerative Technology, Harvard Pilgrim Health Care, Harvard Stem Cell Institute, Harvard University, HCM Registry, HD Medical, Healios K.K., Health Recovery Solutions, Health Sciences Research Institute Germans Trias i Pujol Foundation, Healthstream, HealthTrust, HealthTrust Purchasing Group, HeartBeam, Heartflow, HeartGenetics, HeartHero, HeartIT, Heartseed, HeartSine, HeartWare International, Helix, Hellman & Friedman, HemispheRx Biopharma, Hemostasis, Hemostemix, Henry Ford Health System, Henry Schein, Hetero Labs, Hibernation Therapeutics, High Desert Heart Institute, HighLife, Hikma Pharmaceuticals, Hill-Rom, Hillrom, HitGen, HLH BioPharma Vertriebs, HLS Therapeutics, Holberg EEG, HoliStick Medical, Holmdel Pharmaceuticals, Horizon 2020, Horizon Discovery, Hospira, Hospital of University of Strasbourg, Huadong Medicine, Hua Medtech, Huami, Huapont Pharma, Humacyte, Human Biosystems, Hyloris Pharmaceuticals, iBIO Institute’s PROPEL Center, iCardiac Technologies, Icon, Idorsia, iECURE, ii Ventures, ImagineMIC, IME Medical Electrospinning, Impax Laboratories, ImpediMed, Imperative Care, Imperial College London, Imricor Medical Systems, Indegene Lifesystems, Indiana Biosciences Research Institute, Indiana University, Indigo Biosciences, InfoBionic, InfraReDx, inHealth Medical, inHEART, Innovate UK, Innovation Network Corporation, Innovative Genomics Initiative (IGI), Innova Vascular, Inositec, iNova Pharmaceuticals, InQB8 Medical Technologies, Insilico Biotechnology, InSpire MD, InspireMD, Inspyr Therapeutics, Institute of Human Virology, Integer Holdings, Integrated DNA Technologies, Interleukin Genetics, Intermountain Healthcare, International Society of Heart and Lung Transplantation, Interrad Medical, InterValve, Invitae, Ionis Pharmaceuticals, I Peace, iRhythm Technology, ISA Scientific, Istituti Clinici Scientifici Maugeria, Itamar Medical, IthenaPharma, Itochu, Ivera Medical, Ixaka, Jackson Laboratory, Jacksonville Pharmaceuticals, JanOne, Janssen Pharmaceuticals, Janssen Research & Development, Japan Lifeline, Jarvik Heart, Jasper Capital, JC Medical, JenaValve Technology, Jiangsu Hansoh Pharmaceutical, Ji Xing Pharmaceuticals, JNC Medical, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, Juvise Pharmaceuticals, Jvion, Kaivogen, Kastle Therapeutics, Kennedy Trust For Rheumatology Research, Keystone Heart, Kiniksa Pharmaceuticals, Kiromic Biopharma, Kissei Pharmaceutical, Kitov Pharma, KOL Bio Medical Instruments, Kowa, Kowa Pharmaceuticals America, Kuhnil Pharmaceuticals, Kyma Medical Technologies, Kyoto University, Kyowa Hakko Kirin, L1 Enterprises, Laboratory Corporation of America, Labrox, La Jolla Capital, Lannett, Lantheus Medical Imaging, Laurel Bridge Software, Lee's Pharmaceutical, Leiden University, Leiters, Leonhardt's Launchpads, Leviticus Cardio, LEXEO Therapeutics, Lexington Biosciences, LianBio, Life-Assist, LifeQ, LifeTech Scientific, LifeWatch Services, Ligand Pharmaceuticals, LindaCare, Linear Health Sciences, Lipigon Pharmaceuticals, LivaNova, Lokai Medical, Lombard Medical Technologies, Longeveron, Longitude Capital, Lonza, LORION Enterprises, LSU Health Sciences Center, LUCA Science, LumiraDx, Lund University, Luscii, Luye Pharma Group, mAbsolve, Madison Core Laboratories, MagBioSense, Magnesium Elektron, Mallinckrodt Pharmaceuticals, Maquet Medical Systems, Marina Biotech, Marizyme, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Mast Therapeutics, MateraCor, Materialise, Matrix Medical Network, Mayo Clinic, Maze Therapeutics, MC3 Cardiopulmonary, McGill University, MD Anderson Cancer Center, MDF Instruments, Medable, MedAxiom, MedCision, Medeon Biodesign, Medical City North Hills, Medicure, MedImmune, Medipal Holdings, Medis, MediSafe, Mediso, Medison Pharma, Medisun International, Meditrade, Medovex, MedPac Asia Pacific, Medtronic, Mentice, Merck and Co, Merck KGaA, Merge Healthcare, Mesoblast, Mespere LifeSciences, Metactive, Metrion Biosciences, Micro Interventional Devices, Micro Medical Solutions, MicroPort Scientific, MicroPort Sorin CRM (Shanghai), Microsoft, Milestone Pharmaceuticals, Millar, Millipede, Ministry of Health (Saudi Arabia), Minnetronix, Miravo Healthcare, Mitsubishi Tanabe Pharma, Mobvoi, Mochida Pharmaceutical, Moderna Therapeutics, Molecular Stethoscope, Molex, Montreal Heart Institute, Morphic Therapeutic, Mortara Instruments, Mount Sinai Health System, Mperia Therapeutics, Mpirik, MRI Interventions, MSC, Munich Reinsurance Company, Muscat Pharmacy and Stores, MValve Technologies, Myant, Mylan Laboratories, Myocardial Solutions, Myocarditis Foundation, MyoKardia, Myriad RBM, myTomorrows, N8 Medical, Nagoya University Graduate School of Medicine, Nanion, NanoSurface Biomedical, NASA, Nashville Biosciences, National Cancer Center, National Center for Cardiovascular Diseases, National Cerebral and Cardiovascular Disease Research Center, National Health and Medical Research Council, National Heart, Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Organization for Rare Disorders, National Physical Laboratory, National Research Council Industrial Research Assistance Program, National Science Foundation, National University of Ireland, Galway (NUI Galway), National University of Singapore, Natus Medical, Navidea Biopharmaceuticals, Ncardia, nContact, NeoChord, Neograft Technologies, Neovasc, Neurimmune Therapeutics, NeuroproteXeon, NeuroVive Pharmaceutical Asia, NewAmsterdam Pharma, New Wave Ventures, New York Genome Center (NYGC), New York Institute of Technology, NGM Biopharmaceuticals, NHS Scotland, Nido Surgical, Nightingale Health, NIMIUM Therapeutics, Ninety One, Nipro Corporation, Nissan Chemical Industries, Noden Pharma, North Carolina State University, North Georgia Healthcare, Northwestern Medicine Bluhm Cardiovascular Institute, Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, NovalGen, Novant Health, Novartis, Novasep, Novation, Novella Clinical, Novocardia, Novoheart, Novo Nordisk, Novostia, NTT Medical Center Tokyo, NuCryo Vascular, NuMed, Numerate, Nutricare Costa Rica, NuVascular Technologies, Oberland Capital, Obsidio, Octapharma, Ohio State University, OliX Pharmaceuticals, Olympus, OMEICOS Therapeutics, Omron, On-X Life Technologies, OncoImmune, One Drop, OnFace, Ontario Institute for Cancer Research, Opsens, OptiBiotix, Optina Diagnostics, Opus Medical, OrbusNeich, Orchestra BioMed, Orebro University, Organicell Regenerative Medicine, Orifarm, ORIG3N, Orsini Healthcare Specialty Pharmacy, Ortho-Clinical Diagnostics, Oscor, OtiTopic, Otsuka, Owkin, Owlstone Medical, P+F Products & Features, Paragonix Technologies, Paraza Pharma, Parent Project Muscular Dystrophy, Paul G Allen Family Foundation, Pax Neuroscience, PDL BioPharma, PEDRA Technology, Peijia Medical, Peking University, Penn Medicine, Penumbra, PeptiDream, Pfizer, Pharaon Healthcare‐Droguerie Mercury, PharmAbcine, Pharmabiota, Pharmaceutical Research and Manufacturers of America, Pharma Scientific Research, Pharnext, PhaseBio Pharmaceuticals, Philip Morris, Philips, PhoreMost, Physio-Control, Picard Medical, Pierre Fabre, Pilloxa, Pluriomics, Pluristem Therapeutics, Pohl Boskamp, Poxel, PQ Bypass, Precision BioSciences, Precision Image Analysis, Predictive Health Diagnostics, Premier Inc, Preora Diagnostics, Prevail InfoWorks, Prevencio, Preventice, Primary Peptides, Primordial Genetics, Procella Therapeutics, Procter & Gamble, Procyrion, Profil Institute for Clinical Research, Profusa, Project HOPE, Protek, Proteros biostructures, ProtoKinetix, ProvideGx, Proximo Medical, Prytime Medical Devices, PulseCath, Punjab Province, Q3 Medical Devices, Qingdao Primedicine Pharmaceutical, QT Vascular, Quercis Pharma, Quest Diagnostics, Quick Tube Medical, Quidel, QuiO Technologies, Rain Therapeutics, Rancho Santa Fe Bio, RCC Pharma, Recordati, ReCor Medical, Recovery Force, Red One Medical, Reemo Health, ReFlow Medical, Regenerative Care Network, Regenerative Medicine of China, Regenerative Medicine of Latin America, Regeneron Pharmaceuticals, Regenxbio, Regio Biosciences, Relaxera Pharmazeutische, Relevium, Reliance Life Sciences, Relias, Renovacor, Renova Therapeutics, Renovo, Research Development Foundation, Resverlogix, Retia Medical, Reviva Pharmaceuticals, Revive Therapeutics, Rexgenero, Rex Medical, RFPi, Rigel Pharmaceuticals, Rijuven, Rimidi, Roche, Rocket Pharmaceuticals, Roxwood Medical, Royal Philips Electronics, Royalty Pharma, RQI Partners, RSK Medical, RTI Surgical, RTW Investments, Rush University Medical Center, Sabal Therapeutics, SACCO, Saint Agnes Hospital Foundation, Samsung Biologics, Sanbor Medical, Sandoz, Sanford Burnham Institute, Sanford Health, Sanofi, Savara Pharma, Schrodinger, SciCann Therapeutics, SciClone Pharmaceuticals, ScinoPharm Taiwan, Scipher Medicine, Scohia Pharma, ScottCare Cardiovascular Solutions, scPharmaceuticals, Seattle Childrens Research Institute, Selenity Pharmaceuticals, Sema4, Semmelweis University, Sensible Medical Innovations, Sensifree, Senti Biosciences, Sequent Medical, Serenus Biotherapeutics, Service and Medical Colombia, Shanghai Model Organisms Center, Shenzhen Hepalink Pharmaceutical, Shenzhen Semacare Medical Technology, Shimadzu, Shire Pharmaceuticals, SHL Telemedicine, Shockwave Medical, Siemens Healthineers, SignPath Pharmaceuticals, Silence Therapeutics, Silver Creek Pharmaceuticals, Sinclair Research, Sinomed, Sinotherapeutics, Sintact Medical Systems, Sirtex Medical, SIT Laboratorio Farmaceutico, SK Telecom, SkylineDX, Skyline Therapeutics, Small Business Innovation Research, Smartwise, SNBL CPC, Society for Vascular Surgery Patient Safety Organization (SVS PSO), Society of NeuroInterventional Surgery, Society of Vascular and Interventional Neurology, Sofinnova Partners, Somahlution, SomaLogic, Sonic Healthcare, SonoScape Medical, Sophia Genetics, Sorin Group, Sosei, Sosei Heptares, Southwest Research Institute, Southwest Transplant Alliance, Spacelabs Healthcare, Spectrum Pharmaceuticals, Sphingotec, SQI Diagnostics, SQ Innovation, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, Staten Biotechnology, Stelios Therapeutics, Stem Cell Theranostics, Stempeutics, STENTiT, Stereotaxis,, St Jude Medical, StrideBio, Stryker, Sumocor, SunTech Medical, SuperSonic Imagine, SurModics, Svelte Medical Systems, Swedish Bactiguard, Swixx Biopharma, Symetis, SymphonyAI, Symplmed Pharmaceuticals, SynCardia Systems, Syntach, Syntactx, Tabuk Pharmaceutical, Takeda Pharmaceutical, Talis Biomedical, TARA Biosystems, Taros Chemicals, Tasly Pharmaceuticals, Taxus Cardium Pharmaceuticals, Teijin, Tel Aviv University, Teleflex, Tendyne Holdings, Terason, Tersus Life Sciences, Terumo, Terumo Cardiovascular Systems, Teson Pharma, Teva Pharmaceutical Industries, Texas Instruments, TGen Drug Development, The Foundry, The Hospital for Sick Children, The Medicines Company, Theraclion, Theragene Pharmaceuticals, TheraVasc, Thermo Fisher Scientific, The University of Chicago Medicine, Third Pole Therapeutics, Thoratec, Tibet Rhodiola Pharmaceutical Holding Co, TiGenix, Tiger X Medical, TogetherMD, Topstone Research, Toray, Toronto Innovation Acceleration Partners, toSense, Toshiba America Medical Systems, Transcatheter Technologies, Transgenomic, Translational Sciences, Trigen, Triple Ring Technologies, TriReme Medical, Tris Pharma, TriVascular Technologies, Trophos, Truvic Medical, TTP Group, Twelve, twoXAR, UAB Research Foundation, Ubiquigent, UCB, Ultragenyx Pharmaceuticals, UltraSight, Ultromics, Unetixs Vascular, Unilife, Uniogen, UniQure, United Imaging Healthcare, United Therapeutics, University College London, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California San Francisco, University of Cambridge, University of Cincinnati, University of Colorado, University of Erlangen, University of Iowa, University of Manchester, University of Maryland, University of Miami, University of Nebraska, University of Oslo, University of Ottawa, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Sydney, University of the Highlands and Islands, University of Utah, University of Utah Research Foundation, University of Washington, University of West Indies, University of Wisconsin, University of Wisconsin-Madison,, US Army Medical Research and Material Command, USCI Holdings, Valeant Pharmaceuticals, Valencell, Valo Health, Valtech Cardio, Vance Street Capital, Vasamed, Vascugen, Vascular Flow Technologies, Vascular Graft Solutions, Vascular Simulations, Vascular Solutions, Vascutek, Vasomune Therapeutics, Vasorum, Vector Remote Care, VectraCor, Venclose, Venturis Therapeutics, Venus Medtech, Verantos, Verily, Verity Pharmaceuticals, Verizon, Vesper Medical, Vetex Medical, Viamet Pharmaceuticals, Viant, Vifor Pharma, VirtualScopics, Vitro Biopharma, Vitruvias Therapeutics, Viva Biotech, VivaQuant, VivoSense, Vivo Ventures,, Vizient, VOTIS Subdermal Imaging Technologies, Voyager Therapeutics, Vygon, Wacker Biotech, Wake Forest University, WakeMed Health & Hospitals, Walk Vascular, Wallace H. Coulter Foundation, Washington University in St Louis, WavePoint Medical, Wellcome Trust Sanger Institute, Western New England University, West Pharmaceutical Services, Winthrop-University Hospital, Worcester Polytechnic Institute (WPI), World Heart Federation, WuXi PharmaTech, Xenios, XO1, Yale School of Medicine, Yale University, Yiling Wanzhou International Pharmaceuticals, Yissum Research Development, ZAO Firma Euroservice, ZeClinics, Zelira Therapeutics, Zhittya Genesis Medicine, Zoll Medical, Zora Biosciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.